[go: up one dir, main page]

UA97400C2 - Посилення ефективності хіміотерапії раку - Google Patents

Посилення ефективності хіміотерапії раку

Info

Publication number
UA97400C2
UA97400C2 UAA200913938A UAA200913938A UA97400C2 UA 97400 C2 UA97400 C2 UA 97400C2 UA A200913938 A UAA200913938 A UA A200913938A UA A200913938 A UAA200913938 A UA A200913938A UA 97400 C2 UA97400 C2 UA 97400C2
Authority
UA
Ukraine
Prior art keywords
potentiation
cancer
cancer chemotherapy
patient
preparing
Prior art date
Application number
UAA200913938A
Other languages
English (en)
Russian (ru)
Inventor
Актам Абураб
Марсіу Шедід
Томас Альберт Енглер
Венкатрагхаван Васудеван
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97400(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA97400C2 publication Critical patent/UA97400C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід належить до галузі медицини та стосується комбінованого застосування 7-(2,5-дигідро-4-імідазо[1,2-а]піридин-3-іл-2,5-діоксо-1Н-пірол-3-іл)-9-фтор-1,2,3,4-тетрагідро-2-(1-піперидинілкарбоніл)-піроло[3,2,1-jk]-[1,4]бензодіазепіну із іншим хіміотерапевтичним засобом, з метою лікування раку яєчників, недрібноклітинного раку легенів, раку ободової та прямої кишки та раку шлунка.
UAA200913938A 2007-07-02 2008-06-20 Посилення ефективності хіміотерапії раку UA97400C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02
PCT/US2008/067614 WO2009006043A2 (en) 2007-07-02 2008-06-20 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Publications (1)

Publication Number Publication Date
UA97400C2 true UA97400C2 (uk) 2012-02-10

Family

ID=39737054

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200913938A UA97400C2 (uk) 2007-07-02 2008-06-20 Посилення ефективності хіміотерапії раку

Country Status (22)

Country Link
US (2) US8318713B2 (uk)
EP (1) EP2173348B1 (uk)
JP (2) JP5551589B2 (uk)
KR (1) KR101230085B1 (uk)
CN (2) CN101743005B (uk)
AR (1) AR067112A1 (uk)
AU (1) AU2008270732B2 (uk)
BR (1) BRPI0813789A2 (uk)
CA (1) CA2691587C (uk)
CL (2) CL2008001848A1 (uk)
EA (2) EA023697B1 (uk)
ES (1) ES2561202T3 (uk)
IL (2) IL202237A (uk)
MA (1) MA31677B1 (uk)
MX (1) MX2009013449A (uk)
MY (1) MY154472A (uk)
NZ (1) NZ581355A (uk)
PE (1) PE20090838A1 (uk)
TW (1) TWI428132B (uk)
UA (1) UA97400C2 (uk)
WO (1) WO2009006043A2 (uk)
ZA (1) ZA200908725B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
UA103792C2 (uk) 2009-04-14 2013-11-25 Елі Ліллі Енд Компані Похідна бензодіазепіну для лікування гемопоетичної неоплазми та лейкозу
EP2747761A1 (en) * 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2016175324A1 (ja) * 2015-04-30 2016-11-03 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11066419B2 (en) * 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
JP2024521216A (ja) * 2021-06-03 2024-05-28 ユニバーシティ・オブ・シンシナティ がんの化学増感剤としてのｂｚｄ－１
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CA2477967C (en) 2002-03-05 2010-08-10 Eli Lilly And Company Purine derivatives as kinase inhibitors
CN100549011C (zh) 2002-09-19 2009-10-14 先灵公司 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
EP1768679B1 (en) 2004-07-09 2012-08-22 Agency for Science, Technology and Research Modulation of gsk-3beta and method of treating proliferative disorders
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
EP2460886B1 (en) * 2005-05-04 2014-01-01 University of South Florida Predicting treatment response in cancer subjects
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
CN101743005B (zh) 2013-06-12
JP5551589B2 (ja) 2014-07-16
AR067112A1 (es) 2009-09-30
JP2010532364A (ja) 2010-10-07
PE20090838A1 (es) 2009-07-02
CA2691587C (en) 2013-09-24
MA31677B1 (fr) 2010-09-01
WO2009006043A3 (en) 2009-04-16
KR20100017984A (ko) 2010-02-16
KR101230085B1 (ko) 2013-02-05
ES2561202T3 (es) 2016-02-25
EA201070085A1 (ru) 2010-04-30
US20130039996A1 (en) 2013-02-14
AU2008270732A1 (en) 2009-01-08
EP2173348A2 (en) 2010-04-14
US20100166884A1 (en) 2010-07-01
AU2008270732B2 (en) 2013-01-31
EP2173348B1 (en) 2015-12-09
CN101743005A (zh) 2010-06-16
HK1141236A1 (zh) 2010-11-05
MY154472A (en) 2015-06-30
TWI428132B (zh) 2014-03-01
CA2691587A1 (en) 2009-01-08
TW200911272A (en) 2009-03-16
EA201201155A1 (ru) 2014-11-28
EA023697B1 (ru) 2016-07-29
CN102772416A (zh) 2012-11-14
IL218443A0 (en) 2012-04-30
CL2008001848A1 (es) 2009-05-29
US8318713B2 (en) 2012-11-27
US8648063B2 (en) 2014-02-11
IL202237A0 (en) 2010-06-16
JP2014114297A (ja) 2014-06-26
BRPI0813789A2 (pt) 2014-12-30
WO2009006043A2 (en) 2009-01-08
NZ581355A (en) 2012-04-27
ZA200908725B (en) 2011-02-23
MX2009013449A (es) 2010-01-15
CL2011003046A1 (es) 2012-08-24
EA018447B1 (ru) 2013-08-30
IL202237A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
UA97400C2 (uk) Посилення ефективності хіміотерапії раку
EA024630B9 (ru) Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2009063970A1 (ja) 抗gpr49抗体を用いる癌の診断および治療
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
TN2010000167A1 (en) Organic compounds
LT2197481T (lt) Rnr kompozicija, skirta nesmulkialąstelinio plaučių vėžio (nsclc) gydymui
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
WO2010101964A3 (en) Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell
WO2007092646A3 (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
PH12015501088A1 (en) Dimeric compounds
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
EP2347996A4 (en) PROCESS FOR PRODUCING CARBONITRIDE MIXTURE PARTICLE OR OXYCARBONITRIDE MIXTURE PARTICLE, AND USE THEREOF
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
WO2012087144A3 (en) Methods and means for molecular classification of colorectal cancers
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
WO2012068319A3 (en) Method of treating hematological cancers
WO2012016050A3 (en) Chemoradiotherapy for kras-mutant colorectal cancer
EP2029615B8 (en) A process for the preparation of an oxaliplatin
WO2009072062A3 (en) Derivatives of dihydroxypyrrolidine as anti- cancer compounds
NZ593169A (en) Anticancer compounds
PH12016502298A1 (en) Vegfr2/ang2 compounds